Voyager Therapeutics (VYGR) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Voyager Therapeutics Provides Fourth Quarter and Full Year 2015 Investor Update
March 17, 2016 7:00 AM EDTTop-line Clinical Proof-of-Concept Data for VY-AADC01 for Advanced Parkinsons Disease On Track for Release in the Fourth Quarter of 2016
Strong Cash Position Projected to Support Operations into 2019
CAMBRIDGE, Mass., March 17, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today reported its 2015 fourth quarter and full year financial results, and also provided corporate highlights and upcoming milestones.
2015 was certainly a year of execution on all fronts and... More
